Select Publications
Book Chapters
, 2017, 'Chemoprophylaxis in Inflammatory Bowel Diseases', in Therapeutic Targets for Inflammation and Cancer, WORLD SCIENTIFIC, pp. 57 - 76, http://dx.doi.org/10.1142/9789813148574_0003
Journal articles
, 2026, 'Myeloperoxidase Luminol Reaction – A Novel Faecal Assay for Predicting Colonoscopy Findings in Patients with Ulcerative Colitis: A Pilot Cross-Sectional Clinical Study', Advanced Healthcare Materials, 15, http://dx.doi.org/10.1002/adhm.202501825
, 2026, 'Exploring the Perceptions and Practices of Exclusive Enteral Nutrition Among Adult Patients With Inflammatory Bowel Disease, Gastroenterologists and Dietitians in Australia', JCC Plus, 1, http://dx.doi.org/10.1002/jcc5.70021
, 2025, 'Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium', Jgh Open, 9, http://dx.doi.org/10.1002/jgh3.70322
, 2025, 'On being on the same page: Predictors of gastroenterologist-patient misalignment in inflammatory bowel disease', Patient Education and Counseling, 130, http://dx.doi.org/10.1016/j.pec.2024.108487
, 2024, 'Treatment endpoints in ulcerative colitis: Does one size fit all?', World J Gastrointest Pharmacol Ther, 15, pp. 91591, http://dx.doi.org/10.4292/wjgpt.v15.i2.91591
, 2024, 'Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study', Therapeutic Advances in Chronic Disease, 15, http://dx.doi.org/10.1177/20406223241233203
, 2023, 'Adolescents and young adults communicating with gastroenterologists: Variation in inflammatory bowel disease clinical communication', International Journal of Adolescent Medicine and Health, 35, pp. 347 - 361, http://dx.doi.org/10.1515/ijamh-2023-0078
, 2023, 'Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): A study protocol for a multicentre, colonoscopist-blinded, randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2023-073843
, 2023, 'P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort', Journal of Crohn's and Colitis, 17, pp. i793 - i794, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0793
, 2023, 'S1183 Exclusive Enteral Nutrition Among Adult Patients With Active Crohn’s Disease: A Single Center Experience', American Journal of Gastroenterology, 118, pp. S905 - S905, http://dx.doi.org/10.14309/01.ajg.0000954372.89674.f4
, 2022, 'Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literature.', World J Clin Cases, 10, pp. 2569 - 2576, http://dx.doi.org/10.12998/wjcc.v10.i8.2569
, 2021, 'Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis', European Journal of Gastroenterology and Hepatology, 33, pp. 1524 - 1532, http://dx.doi.org/10.1097/MEG.0000000000002101
, 2021, 'Review of exclusive enteral therapy in adult Crohn's disease', BMJ Open Gastroenterology, 8, http://dx.doi.org/10.1136/bmjgast-2021-000745
, 2021, 'Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey.', BMJ Open Gastroenterol, 8, http://dx.doi.org/10.1136/bmjgast-2020-000581
, 2020, 'Review of therapeutic drug monitoring of infliximab in spondyloarthritis-Catching up with management concepts from other inflammatory conditions.', Br J Clin Pharmacol, 86, pp. 194 - 195, http://dx.doi.org/10.1111/bcp.14129
, 2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, 46, pp. 1037 - 1053, http://dx.doi.org/10.1111/apt.14368
, 2017, 'Editorial: infliximab trough cut-off for perianal Crohn's disease – another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle', Alimentary Pharmacology and Therapeutics, 45, pp. 1279 - 1280, http://dx.doi.org/10.1111/apt.14020
, 2017, 'Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease', Expert Opinion on Drug Safety, 16, pp. 303 - 317, http://dx.doi.org/10.1080/14740338.2017.1269169
Conference Papers
, 2023, 'Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, pp. 793 - 794, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000960367601372&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2023, 'Talking with emerging adults living with inflammatory bowel disease: A qualitative study of clinical communication in gastroenterology', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 175 - 176
, 2022, 'Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn's disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 146 - 147, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852585700223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'PREVALENCE AND IMPACT OF FRAILTY AMONG INFLAMMATORY BOWEL DISEASE OUTPATIENTS', in GUT, BMJ PUBLISHING GROUP, HONG KONG, Hong Kong, pp. A55 - A55, presented at Meeting of the International-Digestive-Disease-Forum (IDDF), HONG KONG, Hong Kong, 22 November 2020 - 23 November 2020, http://dx.doi.org/10.1136/gutjnl-2020-IDDF.102
, 2020, 'Prevalence, risk factors, and impact of frailty among outpatients with inflammatory bowel disease', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 123 - 123, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000589476200177&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Therapeutic drug monitoring-guided biological drug therapy in inflammatory bowel disease: Consensus statements of the Australian Inflammatory Bowel Disease Association (AIBDA) and Gastroenterological Society of Australia (GESA)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 136 - 138, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100247&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'Hygiene Hypothesis: Is the Evidence the Same All over the World?', in Digestive Diseases, pp. 35 - 42, http://dx.doi.org/10.1159/000442922
Conference Presentations
, 2015, 'Medication non-adherence in inflammatory bowel diseases is significantly associated with disability'
Conference Abstracts
, 2026, 'Multi-modal Treatment for Adult Patients with Active Crohn's Disease: A Single Centre Experience', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 20, http://dx.doi.org/10.1093/ecco-jcc/jjaf231.979